regorafenib tablet
Phase 1Active 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ewing Sarcoma
Conditions
Ewing Sarcoma
Trial Timeline
Jun 16, 2023 → Oct 1, 2027
NCT ID
NCT05830084About regorafenib tablet
regorafenib tablet is a phase 1 stage product being developed by Bayer for Ewing Sarcoma. The current trial status is active. This product is registered under clinical trial identifier NCT05830084. Target conditions include Ewing Sarcoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05830084 | Phase 1 | Active |
Competing Products
14 competing products in Ewing Sarcoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Linsitinib | Astellas Pharma | Phase 2 | 52 |
| irinotecan liposome (II) + temozolomide + fluzoparib | Sun Pharmaceutical | Phase 2 | 52 |
| Abemaciclib + Irinotecan + Temozolomide | Eli Lilly | Phase 2 | 52 |
| IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) + IMC-A12 (cixutumumab) | Eli Lilly | Phase 2 | 52 |
| Xaluritamig | Amgen | Phase 1 | 32 |
| CP-751,871 | Pfizer | Phase 1 | 32 |
| CP-751,871 | Pfizer | Phase 1/2 | 40 |
| Palbociclib + Temozolomide + Irinotecan + Topotecan + Cyclophosphamide | Pfizer | Phase 2 | 51 |
| plerixafor + plerixafor + plerixafor | Sanofi | Phase 1/2 | 40 |
| INCB059872 | Incyte | Phase 1 | 30 |
| Lurbinectedin | Jazz Pharmaceuticals | Phase 1/2 | 38 |
| Lurbinectedin | Jazz Pharmaceuticals | Phase 1/2 | 38 |
| Cabozantinib | Exelixis | Phase 1 | 30 |
| INBRX-109 + Irinotecan + Temozolomide + carboplatin + pemetrexed + Leucovorin + Fluorouracil | Inhibrx Biosciences | Phase 1 | 28 |